Fate Therapeutics: Revolutionizing Cellular Immunotherapies
Fate Therapeutics is a San Diego-based biopharmaceutical company researching and developing a novel class of cellular immunotherapies for the treatment of cancer and immune disorders. Biotech Investments sees Fate Therapeutics’ approach as revolutionizing the field of cell therapy.
Fate Therapeutics uses renewable master induced pluripotent stem cell (iPSC) lines generated from the company’s own iPSC product platform to produce cellular immunotherapies for various oncological and immunological conditions. In addition, the company is working on a number of first-in-class allogeneic cell therapy products using cells from healthy donors, which can be modified to improve the cell’s therapeutic function.
The Americans have a broad clinical pipeline for hematologic malignancies, solid tumors and immune disorders. The company is well positioned and has excellent future prospects.
We are looking at Fate Therapeutics as a TOP PICK.
Would you like to know more about other biotech hot stocks? You can find lots of great articles in our free monthly Biotech Investments MAGAZINE.
- Just send an email with “MAGAZINE” to firstname.lastname@example.org
- You will receive it immediately by email
- Enjoy reading, it’s entirely free